Tesamorelin
GHRH analogue. Pharmacokinetics vary between studied medicinal formulations.
Search names: Tesa
Evidence
Medicine data · formulation matters
Describes the linked sources, not an overall score for product quality or effectiveness.Half-life
EGRIFTA WR: 11 minutes after a single subcutaneous dose in healthy participants. Other formulations have different values.
Statistics reference: About 10 minutes
Human information in catalogueContext and sources for the statistics reference
Catalogue quick fact; current preparations 8–11 minutes, older formulation 26–38 minutes.
About 10 minutes · Catalogue information from PeptideTracker.ai; read the limitation above. PeptideTracker.ai · Tesamorelin ↗
Half-life, duration of effect and shelf life are different measures. Catalogue values may differ between variants and administration routes. Curves continue to use their stated statistics reference.
Adverse effects and limitations
Adverse effects are not fully mapped in this entry. Consult the sources for the specific compound and use.
Sources and further reading
Vital · user-supplied screen recordings, 1 Nov 2026
Study / medicine dataEGRIFTA WR · prescribing information↗Find researchPubMed · Tesamorelin↗Research information, not a personal dosing plan. Last reviewed: 2026-11-01.